<DOC>
	<DOCNO>NCT02045979</DOCNO>
	<brief_summary>Investigate pharmacokinetics , safety tolerability BI695501 establish pharmacokinetic similarity BI 695501 adalimumab .</brief_summary>
	<brief_title>Pharmacokinetics Safety Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Inclusion criterion : Healthy male accord follow criterion : 1 . Based upon complete medical history , include physical examination , vital sign ( blood pressure [ BP ] pulse rate [ PR ] ) , 12lead electrocardiogram ( ECG ) , clinical laboratory test ; 2 . Agegreater equal 18 year less equal 55 year ; 3 . Body mass index ( BMI ) =18.5 =29.9 kg/m2 ; 4 . Signed date write informed consent prior admission study accordance GCP local legislation . Exclusion criterion : 1 . Any clinically relevant abnormal find medical examination ( include blood pressure ( BP ) , pulse rate ( PR ) , electrocardiogram ( ECG ) deviate normal clinical relevance ; 2 . Any evidence clinically relevant previous concomitant disease judge investigator include gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological , hormonal disorder , diseases central nervous system ( epilepsy ) , psychiatric disorder , neurological disorder ; 3 . History relevant orthostatic hypotension , faint spell , blackout ; 4 . Chronic relevant acute infection . A negative result human immunodeficiency virus ( HIV ) , Hepatitis B ( Hep B ) , hepatitis C ( Hep C ) require participation ; 5 . History relevant allergy/hypersensitivity ( include allergy drug excipients ) ; 6 . Intake prescribed overthecounter drug long halflife ( great 24 hour ) within least one month least 5 halflives respective drug ( whichever longer ) prior administration trial ; 7 . Previous exposure biologic drug ; 8 . Use drug might reasonably influence result trial prior dose time trial ; 9 . Intake investigational drug another trial within two month prior intake study medication trial intake investigational drug course trial ; 10 . Smoker ( great 10 cigarette great 3 cigar great 3 pipes/day ) ; 11 . Inability refrain smoking day confinement trial site ; 12 . History alcohol abuse ( estimate average 4 units/day ) ; 13 . Unwillingness/iInability refrain intake alcoholic beverage 48 hour prior study medication administration Day 7 post study medication administration ; 14 . Unwillingness/inability limit alcohol intake maximum three unit per day e.o.s . ; 15 . Current drug abuse ; 16 . Blood donation ( 100 mL within four week prior administration study medication trial ) ; 17 . Vigorous exercise 72 hour prior dose . Unwilling avoid vigorous exercise 7 day post dose . Contact sport avoid entire study ; 18 . Any outofrange laboratory value consider clinically significant investigator ; subject creatine kinase ( CK ) value three time upper limit normal ( ULN ) Day 1 exclude participation ; 19 . Subjects consider unsuitable inclusion investigator ( e.g. , inability understand comply study requirement presence condition , opinion investigator , would allow safe participation study ) ; 20 . Inability comply dietary regimen trial site . 21 . Subjects know Human immunodeficiency virus ( HIV ) , Acquired Immunodeficiency Syndrome , clinically significant immunological disorder , autoimmune disorder , ( e.g. , Rheumatoid arthritis ( RA ) , lupus erythematosus , scleroderma , etc . ) ; 22 . Subject receive live attenuated vaccine within 12 week prior enrol trial ; 23 . Positive find Interferongammarelease assay test ( IGRAT ) . In case screen visit IGRA result indeterminate , subject PPD skin test perform , provide screening period timeframe maintain . If , subject enrol study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>